Results 31 to 40 of about 11,486 (263)

PRMT9 Aggravated Dopaminergic Neurodegeneration in Parkinson's Disease Model by Facilitating the Degradation of DUSP26 and Inducing Mitochondrial Dysfunction

Advanced Science, EarlyView.
In the pathological state of PD induced by MPP+, the upregulated PRMT9 in dopaminergic neurons translocates into mitochondrion and interacts with DUSP26 and catalyzes its arginine methylation, leading to the ubiquitin‐proteasomal degradation of DUSP26 mediated by Trim32.
Tengfei Liu, Xiaomeng Song, Xin Guo, Rui Xiao, Ru Sun, Qiuran Ji, Lu Yu, Yiquan Li, Qingyi Fu, Qidi Xue, Lingjun Kong, Lin Chen, Chengjiang Gao, Huiqing Liu   +13 more
wiley   +1 more source

Placental Site Trophoblastic Tumor Acquires Immune Functions by Incorporating Host Maternal Genes

Advanced Science, EarlyView.
PSTT cells, through cell fusion with B cells, incorporate abundant non‐inherited maternal genes that are detectable by DNIMA. These hybrid cells acquire immunotherapy‐resistant genetic changes and increase the expression of B cell‐derived immune‐related molecules such as Ig, HLA, LILRB, SIGLEC10, and so on, creating an immunotolerant environment around
Kyosuke Kagami, Masanori Ono, Yasunari Mizumoto, Tatsuhito Kanda, Takashi Iizuka, Takiko Daikoku, Shin‐ichi Horike, Akira Hattori, Akihito Horie, Sachiko Minamiguchi, Tomoko Fujiwara, Kazuyoshi Hosomichi, Atsushi Tajima, Hirokazu Usui, Kaoru Abiko, Hiroshi Fujiwara   +15 more
wiley   +1 more source

What to Expect When Expecting With Systemic Lupus Erythematosus (SLE) : A Population-Based Study of Maternal and Fetal Outcomes in SLE and Pre-SLE.

, 2016
OBJECTIVE: To assess maternal and fetal outcomes associated with subclinical (pre-systemic lupus erythematosus [SLE] and SLE presenting up to 5 years postpartum) and prevalent maternal SLE during pregnancy compared with the general population.
Arkema, Elizabeth V, Salmon, Jane E,, Svenungsson, Elisabet, Simard, Julia F,, Simard, Julia F, Arkema, Elizabeth V,, Sjöwall, Christopher,, Palmsten, Kristin, Sjöwall, Christopher, Palmsten, Kristin,, Svenungsson, Elisabet,, Salmon, Jane E   +11 more
core   +1 more source

Beyond Potency: Emerging Determinants and Optimization Strategies Enhancing Therapeutic Efficacy of Adult Stem Cells

Advanced Science, EarlyView.
Adult stem cell therapy requires more than high in vitro potency. This review proposes a systems framework in which cell‐intrinsic programs, instructive microenvironmental cues, and pre‐/post‐delivery engineering are co‐designed under standardized translational rules.
Soo‐Rim Kim, Yun Jae Jung, Hwa‐Yong Lee   +2 more
wiley   +1 more source

An Integrative Strategy Delineates Modular Metabolic Remodeling and Potential Therapeutic Targets Across Metabolic Diseases

Advanced Science, EarlyView.
An integrative single‐cell atlas across multiple metabolic diseases reveals coordinated metabolic modules and disease‐shared versus disease‐specific pathway activities. By systematically comparing scoring strategies, a robust RankAve framework is established. Coupled with network analysis and drug‐target prediction, this resource uncovers cross‐disease
Kuan Yang, Congxue Hu, Hang Zhao, Xiao Peng, Yiming Yan, Jiasi Wang, Wenqi Jiang, Depeng Mu, Yan Cao, Xia Li, Yunpeng Zhang   +10 more
wiley   +1 more source

Better 10‐Year Cerebrovascular Outcome After Transplant Than on Standard‐Care in Sickle Cell Anemia: DREPAGREFFE Trial

American Journal of Hematology, EarlyView.
ABSTRACT Management of cerebral vasculopathy in sickle cell anemia (SCA) includes standard‐care, that is, chronic transfusion (CT) or hydroxyurea, and hematopoietic cell transplantation (HCT). DREPAGREFFE‐1 (December 2010/June 2013), a French multicenter trial, was the first prospective trial comparing standard‐care to match sibling donor (MSD)‐HCT in ...
Francoise Bernaudin, Suzanne Verlhac, Elisabeth Ducros‐Miralles, Cécile Arnaud, Isabelle Genty, Marie Petras, Catherine Paillard, Gonzalo De Luna, Benoit Meunier, Isabelle Thuret, Annie Kamdem, Corinne Pondarré, Giovanna Cannas, Christelle Chantalat‐Auger, Nadia Firah, Sophie Pertuisel, Laure Joseph, Florence Missud, Mariane de Montalembert, Corinne Guitton, Claire Pluchart, Valentine Brousse, Monique Elmaleh, Vincent Gajdos, Emmanuella Leveillé, Ekaterina Belozertseva, Mabel Gaba, Catherine Poirot, Virginie Barraud‐Lange, Philippe Chadebech, France Pirenne, Myriam Bernaudin, Bénédicte Neven, Pierre Frange, Marie Angoso, Karima Yakouben, Bénédicte Bruno, Nathalie Dhédin, Jean‐Hugues Dalle, Regis Peffault Delatour, Camille Jung   +40 more
wiley   +1 more source

The evidence-practice gap in immunotherapy for recurrent pregnancy loss:a critical narrative review of current treatments

Many clinicians suspect immune problems when treating women with unexplained recurrent pregnancy loss (RPL); however, we lack evidence that immunotherapy helps.
Krog, Maria Christine, Lathi, Ruth Bunker, Nielsen, Henriette Svarre, Vomstein, Kilian, Møller, Ida Behrendt   +4 more
core   +1 more source

Exploring the Burden on Patients Living With and Receiving Treatment for Immune Thrombocytopenia (ITP): Patient and Physician Perceptions From the ITP World Impact Survey (I‐WISh) 2.0

American Journal of Hematology, EarlyView.
ABSTRACT Limited data exist on how patients and physicians perceive immune thrombocytopenia (ITP) symptoms and treatment‐related burden. I‐WISh (ITP World Impact Survey) 2.0 surveyed 1018 patients and 431 physicians in 15 countries to characterize the impact of ITP and its treatments on patients.
Nichola Cooper, James Bussel, Waleed Ghanima, Drew Provan, Yoshiaki Tomiyama, Ming Hou, Donald M. Arnold, Cristina Santoro, Francesco Zaja, Barbara Lovrencic, Mervyn Morgan, Michal Winograd, Jennifer DiRaimo, Danielle Boyle, Olivera Rajkovic‐Hooley, Meritxell Vendranas, Susan Frade, Caroline Kruse   +17 more
wiley   +1 more source

Correction of Ineffective Erythropoiesis and Normalization of Iron Homeostasis After Exagamglogene Autotemcel in Transfusion‐Dependent β‐Thalassemia

American Journal of Hematology, EarlyView.
ABSTRACT Exagamglogene autotemcel (exa‐cel) is a one‐time, ex vivo, CRISPR‐Cas9 gene edited cell therapy approved for patients with transfusion dependent β‐thalassemia (TDT) aged 12–35 years. In a Phase 3 study (CLIMB THAL‐111), exa‐cel treatment resulted in reactivation of fetal hemoglobin and increases in total hemoglobin, leading to transfusion ...
Sujit Sheth, Selim Corbacioglu, Josu de la Fuente, Mattia Algeri, Joachim Rupprecht, Kevin H. M. Kuo, Ami J. Shah, Peter Lang, Hayley Merkeley, Ben Carpenter, Markus Y. Mapara, Robert I. Liem, Stephan Grupp, Yogi Chopra, Amanda M. Li, Janet L. Kwiatkowski, Melanie Kirby‐Allen, Maria Domenica Cappellini, Antonis Kattamis, Sakellarios Zairis, Tina Liu, William Hobbs, Haydar Frangoul, Franco Locatelli, Roland Meisel, on behalf of the CLIMB THAL‐111 and CLIMB‐131 Study Groups   +25 more
wiley   +1 more source

Non-immunologic hydrops fetalis: study of 86 autopsies

, 1996
FAPERJFundação Oswaldo Cruz. Instituto Fernandes Figueira. Departamento de Anatomia Patológica. Rio de Janeiro, RJ, BrasilFundação Oswaldo Cruz. Instituto Fernandes Figueira. Departamento de Anatomia Patológica. Rio de Janeiro, RJ, BrasilFundação Oswaldo
Garcia, Aparecida Gomes Pinto, Nascimento, Jussara Pereira do, Cubel, Rita de Cassia Nasser, Marques, Regina Lucia Souza, Pegado, Claudia Schwartz, Bem Ramos, Hilda Irecê de   +5 more
core